NCM
TEVA icon

Novare Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Novare Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,025
Closed -$202K – 110
2016
Q2 		$202K Buy
+4,025
New +$214K 0.05% 106

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Novare Capital Management's TEVA Position: Q3 2016 in Review

Novare Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2016, closing a stake of 4,025 shares — an estimated $202K sold.

Novare Capital Management first reported a position in TEVA in Q2 2016 and held it in 1 quarter. The position peaked at $202K in Q2 2016. 798 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

  • Novare Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2016 after selling out during the quarter.
  • Novare Capital Management sold 4,025 Teva Pharmaceutical Industries Limited shares in Q3 2016, an estimated $202K.
  • Novare Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2016 and held it in 1 quarter.
  • Novare Capital Management's Teva Pharmaceutical Industries Limited position peaked at $202K in Q2 2016.
  • 798 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2016.

Based on Novare Capital Management's 13F filing for Q3 2016, filed 4 Nov 2016.